1. Home
  2. SNDX vs BCSF Comparison

SNDX vs BCSF Comparison

Compare SNDX & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • BCSF
  • Stock Information
  • Founded
  • SNDX 2005
  • BCSF 2015
  • Country
  • SNDX United States
  • BCSF United States
  • Employees
  • SNDX N/A
  • BCSF N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • BCSF Finance/Investors Services
  • Sector
  • SNDX Health Care
  • BCSF Finance
  • Exchange
  • SNDX Nasdaq
  • BCSF Nasdaq
  • Market Cap
  • SNDX 1.1B
  • BCSF 1.0B
  • IPO Year
  • SNDX 2016
  • BCSF 2018
  • Fundamental
  • Price
  • SNDX $9.00
  • BCSF $15.25
  • Analyst Decision
  • SNDX Strong Buy
  • BCSF Buy
  • Analyst Count
  • SNDX 10
  • BCSF 2
  • Target Price
  • SNDX $35.80
  • BCSF $16.50
  • AVG Volume (30 Days)
  • SNDX 1.8M
  • BCSF 285.4K
  • Earning Date
  • SNDX 07-31-2025
  • BCSF 08-05-2025
  • Dividend Yield
  • SNDX N/A
  • BCSF 11.02%
  • EPS Growth
  • SNDX N/A
  • BCSF N/A
  • EPS
  • SNDX N/A
  • BCSF 1.75
  • Revenue
  • SNDX $43,722,000.00
  • BCSF $284,993,000.00
  • Revenue This Year
  • SNDX $426.77
  • BCSF N/A
  • Revenue Next Year
  • SNDX $98.31
  • BCSF N/A
  • P/E Ratio
  • SNDX N/A
  • BCSF $8.73
  • Revenue Growth
  • SNDX N/A
  • BCSF N/A
  • 52 Week Low
  • SNDX $8.58
  • BCSF $13.20
  • 52 Week High
  • SNDX $25.07
  • BCSF $19.21
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 38.70
  • BCSF 49.09
  • Support Level
  • SNDX $8.77
  • BCSF $14.88
  • Resistance Level
  • SNDX $9.50
  • BCSF $15.17
  • Average True Range (ATR)
  • SNDX 0.53
  • BCSF 0.25
  • MACD
  • SNDX -0.04
  • BCSF 0.01
  • Stochastic Oscillator
  • SNDX 14.13
  • BCSF 53.74

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About BCSF Bain Capital Specialty Finance Inc.

Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.

Share on Social Networks: